Patents by Inventor Randy W. Jackson

Randy W. Jackson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta-lactamase inhibitors
    Patent number: 11414435
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: August 16, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Penicillin-binding protein inhibitors
    Patent number: 11267826
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 8, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Guo-Hua Chu, Randy W. Jackson, Jodie Hamrick, Matthew Lucas, Steven A. Boyd, Jiangchao Yao, Eugen F. Mesaros
  • Beta-lactamase inhibitors
    Patent number: 11008346
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: May 18, 2021
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Randy W. Jackson, Jodie Hamrick, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20200361962
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: February 21, 2020
    Publication date: November 19, 2020
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Randy W. JACKSON, Jodie HAMRICK, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20200317698
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: May 1, 2020
    Publication date: October 8, 2020
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT, Randy W. JACKSON
  • PENICILLIN-BINDING PROTEIN INHIBITORS
    Publication number: 20200102331
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: May 25, 2018
    Publication date: April 2, 2020
    Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Randy W. JACKSON, Jodie HAMRICK, Matthew Lucas, Steven A. BOYD, Jiangchao YAO, Eugen F. MESAROS
  • Beta-lactamase inhibitors
    Patent number: 10464952
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 5, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson, Jodie Hamrick, Allison L. Zulli, Eugen F. Mesaros, Steven A. Boyd
  • Beta-lactamase inhibitors
    Patent number: 10125152
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 13, 2018
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20180291039
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: June 7, 2018
    Publication date: October 11, 2018
    Inventors: Christopher J. BURNS, Daniel C. PEVEAR, Robert E. Lee TROUT, Randy W. Jackson, Jodie HAMRICK, Allison L. ZULLI, Eugen F. MESAROS, Steven A. BOYD
  • Beta-lactamase inhibitors
    Patent number: 10093685
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 9, 2018
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Beta-lactamase inhibitors
    Patent number: 9926336
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: March 27, 2018
    Assignee: VENATORX PHARMACEUTICALS
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Randy W. Jackson, Jodie Hamrick, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20170342093
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: August 11, 2017
    Publication date: November 30, 2017
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT, Randy W. JACKSON
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20170342092
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: August 11, 2017
    Publication date: November 30, 2017
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Randy W. JACKSON, Jodie HAMRICK, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT
  • Beta-lactamase inhibitors
    Patent number: 9783555
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 10, 2017
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Randy W. Jackson, Jodie Hamrick, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Beta-lactamase inhibitors
    Patent number: 9771382
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: September 26, 2017
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20170226135
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 10, 2017
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Randy W. JACKSON, Jodie HAMRICK, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT
  • ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS
    Publication number: 20170145037
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases and methods thereof. In some embodiments, the compounds described herein are biologically hydrolyzed to a beta-lactamase inhibitor. In certain embodiments, the compounds described herein are useful for the treatment of bacterial infections.
    Type: Application
    Filed: December 1, 2016
    Publication date: May 25, 2017
    Inventors: Christopher J. BURNS, Denis DAIGLE, Jodie HAMRICK, Bin LIU, Randy W. JACKSON, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT
  • Beta-lactamase inhibitors
    Patent number: 9637504
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: May 2, 2017
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Randy W. Jackson, Jodie Hamrick, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20160304539
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 20, 2016
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT, Randy W. JACKSON
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20160264598
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 15, 2016
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Randy W. JACKSON, Jodie HAMRICK, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT